A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database
Abstract Certolizumab pegol (CZP), a PEGylated anti-tumor necrosis factor alpha (TNF-α) biologic, is approved for treating autoimmune disorders, including psoriatic arthritis (PsA). Despite its good therapeutic effects, its real-world safety remains limited. This study aims to evaluate the real-worl...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-13502-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|